Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)

Samuel K. Kulp, Chang Shi Chen, Da Sheng Wang, Ching Yu Chen, Ching Shih Chen

研究成果: Comment/debate同行評審

摘要

This article (1) has been retracted at the request of the editors. Following an institutional review by Ohio State University, the primary affiliation for several of the authors, it was determined that data in Fig. 4A was falsified. As a result of these findings, the institution recommended retraction and, upon internal review, the editors agreed with this recommendation. A copy of this Retraction Notice was sent to the last known e-mail addresses for all authors. Two authors (Samuel K. Kulp and Ching-Shih Chen) agreed to the retraction, and three authors (Chang-Shi Chen, Da-Sheng Wang, and Ching-Yu Chen) did not respond.

原文English
頁數1
期刊Clinical Cancer Research
25
發行號9
DOIs
出版狀態Published - 2006 九月 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

指紋 深入研究「Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)」主題。共同形成了獨特的指紋。

引用此